Fecal Lactoferrin Testing: Quantitative vs Qualitative
Use quantitative fecal lactoferrin testing rather than qualitative testing for ulcerative colitis monitoring and diagnosis, as the commercial qualitative assay (cutoff 7.25 mg/g) is the only validated format with established diagnostic accuracy for detecting endoscopic inflammation. 1
Key Distinction
The evidence base for fecal lactoferrin in inflammatory bowel disease is built almost entirely on qualitative testing that reports results as simply "positive" (elevated) or "negative" (normal), corresponding to a cutoff of 7.25 mg/g 1. This is fundamentally different from fecal calprotectin, where multiple quantitative cutoffs (50,150,250 mg/g) have been validated and guide clinical decision-making.
Evidence-Based Performance
The 2023 AGA guideline analyzed 9 studies examining fecal lactoferrin for detecting moderate to severe endoscopic inflammation in UC patients 1:
- Sensitivity: 83% (95% CI: 72-90%)
- Specificity: 75% (95% CI: 59-87%)
- Validated cutoff range: 7.25-10 mg/g (commercial assays use 7.25 mg/g)
Clinical Performance by Pretest Probability
In asymptomatic UC patients (low pretest probability, 15% prevalence of moderate-severe inflammation):
- False negative rate: 2.6% with normal lactoferrin (<7.25 mg/g) 1
- False positive rate: 21.2% with elevated lactoferrin 1
In mildly symptomatic UC patients (intermediate pretest probability, 50% prevalence):
Why Qualitative Testing Dominates
Unlike calprotectin where quantitative values inform different clinical thresholds, lactoferrin studies consistently report only single cutoff performance 1. The commercial assays are designed as binary tests (positive/negative), making qualitative testing the standard approach. The evidence synthesis found no validated quantitative thresholds beyond the 7.25 mg/g cutoff 1.
Critical Limitation
The 2025 ECCO-ESGAR guideline emphasizes that quantitative tests should be used for fecal calprotectin because qualitative tests have limited value 2. However, this recommendation specifically addresses calprotectin, not lactoferrin. For lactoferrin, the qualitative format at 7.25 mg/g is the validated approach.
Practical Algorithm
For UC monitoring in symptomatic remission:
- Use qualitative fecal lactoferrin (cutoff 7.25 mg/g) as part of biomarker-based monitoring every 6-12 months 1
- Normal lactoferrin (<7.25 mg/g): Rules out active inflammation; avoid routine endoscopy 1
- Elevated lactoferrin (>7.25 mg/g): Consider endoscopic assessment or repeat testing in 3-6 months 1
For symptomatic UC patients:
- Moderate-severe symptoms: Elevated lactoferrin (>7.25 mg/g) can rule in active inflammation and guide treatment adjustment without mandatory endoscopy 1
- Mild symptoms with elevated lactoferrin: Proceed to endoscopic assessment rather than empiric treatment adjustment 1
Important Caveats
- Fecal lactoferrin has more limited evidence compared to calprotectin (9 studies vs 12+ studies) 1
- Some studies defined endoscopic inflammation as MES 1-3 rather than the more clinically relevant MES 2-3, potentially affecting accuracy 1
- Certainty of evidence is very low due to selective reporting of cutoffs and high heterogeneity 1
- Lactoferrin may be less accurate in isolated ileal Crohn's disease 2, 3
- Not specific to IBD—elevated in any neutrophilic intestinal inflammation including infections 1, 4
Bottom Line
The question of "quantitative vs qualitative" is somewhat moot for lactoferrin in IBD—the validated clinical approach uses a single binary cutoff (7.25 mg/g), which functions as a qualitative test even when measured quantitatively. Unlike calprotectin where multiple quantitative thresholds guide different clinical decisions, lactoferrin testing relies on a positive/negative result at one established cutoff 1.